Company interfaces with a world-renowned clinician for the launch of their innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Andrew Siderowf, MD, MS , has accepted to serve on neuropacs’ Board of Clinical Advisors.
Dr. Siderowf is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD at Duke University, residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester. Dr. Siderowf’s clinical practice focuses on the diagnosis and management of patients with Parkinson’s disease and related disorders. His research encompasses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures. He also serves on the safety monitoring boards of several ongoing multi-center clinical trials.
“Dr. Siderowf has leadership roles in multi-center clinical studies related to Parkinson’s disease. He is the Co-PI of the Parkinson Progression Marker Initiative (PPMI) and lead investigator for the Parkinson Study Group (PSG) in the SPARK study of passive anti-alpha synuclein immunotherapy for Parkinson’s disease”, stated Dr. Martin Handfield, neuropacs’ President and CEO. He added: “Dr. Sidereowf is a leader and an influencer in Parkinson’s Disease diagnostic and we are confident that neuropacs will benefit from his experience, expertise and insight. “I’m delighted to help the neuropacs team for the mutual benefit of our patients. The company has developed a breakthrough medical technology that may enable earlier intervention and improved patient outcomes, which is much needed clinically”, commented Dr. Siderowf.
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.